HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Otsuka, M Articles by Abe, S Search for Related Content PubMed PubMed Citation Articles by Otsuka, M Articles by Abe, S Topic Collections Relevant Article

Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist

Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan

Correspondence to:
Correspondence to:
Dr H Takahashi
Third Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo 060-8543, Japan; htaka{at}sapmed.ac.jp

ABSTRACT
Background: Signalling of angiotensin II via angiotensin II type 1 receptor (AT1) promotes cardiac and renal fibrosis, but its role in lung fibrosis is little understood. Using a rat bleomycin (BLM) induced model of pulmonary fibrosis, we examined the expression of AT1 in the lung and the effect of an AT1 antagonist on pulmonary fibrosis.

Methods: Adult male Sprague-Dawley rats were given 0.3 mg/kg BLM intratracheally. Two days earlier they had received 10 mg/kg/day of the AT1 antagonist candesartan cilexetil mixed in the drinking water. AT1 expression in the lungs was examined by immunohistochemistry and immunoblot methods. The effect of the AT1 antagonist on pulmonary fibrosis was studied by analysis of bronchoalveolar lavage (BAL) fluid, histopathology, and hydroxyproline assay.

Results: Immunohistochemical studies showed overexpression of AT1 in inflammatory immune cells, alveolar type II cells, and fibroblasts. A quantitative assay for AT1 showed that AT1 expression was significantly upregulated in cells from BAL fluid after day 3 and in the lung homogenates after day 21. Candesartan cilexetil significantly inhibited the increase in total protein and albumin, as well as the increase in total cells and neutrophils in BAL fluid. On day 21 candesartan cilexetil also ameliorated morphological changes and an increased amount of hydroxyproline in lung homogenates. In addition, BLM increased the expression of transforming growth factor (TGF)-ß₁ in BAL fluid on day 7; this increase was significantly reduced by candesartan cilexetil.

Conclusion: AT1 expression is upregulated in fibrotic lungs. Angiotensin II promotes lung fibrosis via AT1 and, presumably, in part via TGF-ß₁.

Keywords: angiotensin II type 1 receptor; candesartan cilexetil; pulmonary fibrosis

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2004 59: 1. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				B. D. Uhal The role of apoptosis in pulmonary fibrosis Eur. Respir. Rev., December 1, 2008; 17(109): 138 - 144. [Abstract] [Full Text] [PDF]

				H. S. Bedair, T. Karthikeyan, A. Quintero, Y. Li, and J. Huard Angiotensin II Receptor Blockade Administered After Injury Improves Muscle Regeneration and Decreases Fibrosis in Normal Skeletal Muscle Am. J. Sports Med., August 1, 2008; 36(8): 1548 - 1554. [Abstract] [Full Text] [PDF]

				M. M. Martin, J. A. Buckenberger, J. Jiang, G. E. Malana, D. L. Knoell, D. S. Feldman, and T. S. Elton TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L790 - L799. [Abstract] [Full Text] [PDF]

				G. B. J. Mancini Clarion Call for Trials Assessing "Cardiopulmonary" Agents To Reduce Morbidity and Mortality in Inflammatory Lung Diseases Chest, April 1, 2007; 131(4): 950 - 951. [Full Text] [PDF]

				M Molina-Molina, A Serrano-Mollar, O Bulbena, L Fernandez-Zabalegui, D Closa, A Marin-Arguedas, A Torrego, J Mullol, C Picado, and A Xaubet Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis Thorax, July 1, 2006; 61(7): 604 - 610. [Abstract] [Full Text] [PDF]

				G.B. J. Mancini, M. Etminan, B. Zhang, L. E. Levesque, J. M. FitzGerald, and J. M. Brophy Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2554 - 2560. [Abstract] [Full Text] [PDF]

				J. C. Grutters and R. M. du Bois Genetics of fibrosing lung diseases Eur. Respir. J., May 1, 2005; 25(5): 915 - 927. [Abstract] [Full Text] [PDF]